Omega Therapeutics, INC 8-K filings

Omega Therapeutics has filed for Chapter 11 bankruptcy and entered into an asset purchase agreement with Pioneering Medicines 08-B, Inc., an affiliate of Flagship Pioneering, Inc., to sell substantially all of its assets.

Omega Therapeutics has filed for Chapter 11 bankruptcy and obtained debtor-in-possession (DIP) financing to continue operations while pursuing a sale of its assets.

Omega Therapeutics has entered a Restructuring Support Agreement (RSA) with Flagship Pioneering affiliates, contemplating a potential sale of assets and a Chapter 11 filing.

Omega Therapeutics reports the resignation of two board members and the appointment of a new director, along with a reclassification of another director to balance board membership.

Omega Therapeutics received a notice of default from Banc of California, who declared the company's loan immediately due and payable, citing concerns over cash runway, financing, solvency, pre-clinical programs, stock price, and corporate governance.

Christian S. Schade resigned from his position as Chair and member of the Board of Directors of Omega Therapeutics, Inc., effective immediately on January 10, 2025.

Omega Therapeutics is considering a non-binding proposal from Mirai Bio to acquire its rights and obligations under a research collaboration agreement and a license to its platform in exchange for assuming $8 million of debt.

Omega Therapeutics has appointed Ravi Mehrotra, Ph.D. to its Board of Directors, while also announcing the resignations of John Mendlein, Ph.D. and Richard A. Young, Ph.D.

Omega Therapeutics has appointed Kaan Certel as its new President and CEO, effective immediately, and entered into amended shared space agreements with several Flagship Pioneering affiliates.

Omega Therapeutics has appointed Robert L. Rosiello as a Class I director, effective October 2, 2024.

Omega Therapeutics has entered into amended and new shared space agreements with several Flagship Pioneering affiliates, adjusting sublease arrangements at its Cambridge facility.

Omega Therapeutics reported its second quarter 2024 financial results, highlighted progress in its MYCHELANGELO I clinical trial, and strengthened its leadership team.

Omega Therapeutics' stockholders approved an amendment to the company's Restated Certificate of Incorporation, extending exculpation provisions to certain officers, as permitted by recent changes in Delaware law.

Omega Therapeutics has amended the employment agreement for Barbara Chan, who will become the principal financial officer, detailing her compensation and severance terms.

Omega Therapeutics has announced the departure of its Chief Medical Officer, Yan Moore, and the appointment of Kaan Certel as Chief Business Officer, effective May 28, 2024.

Omega Therapeutics reports progress in its MYCHELANGELO I trial, presents new preclinical data, and announces Q1 2024 financial results, with cash runway extended into Q1 2025.

Omega Therapeutics' Chief Financial Officer, Joshua Reed, will depart on May 31, 2024, with Barbara Chan appointed as the new principal financial officer, effective the same date.

Omega Therapeutics is focusing resources on near-term milestones, including its lead program OTX-2002, and has extended its cash runway into Q1 2025.